SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): AUGUST 1, 2008
STEM CELL THERAPY INTERNATIONAL, INC.
(Exact Name of Registrant as Specified in Its Charter)
(State or other jurisdiction of
incorporation or organization)
|(Commission File Number)|| |
203 N. Lois Avenue, 9th Floor, Tampa, FL 33607
(Address of principal executive offices zip code)
(Registrants telephone number, including area code)
(former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))|
|ITEM 5.02||ELECTION OF DIRECTOR OR PRINCIPAL OFFICER|
Mr. Stark, who is the President of Stem Cell Therapy International, Inc. (the Company) has been appointed to the Board of Directors and has been elected as the Chairman of the Board of Directors until his respective successor is elected and qualified or until his earlier resignation, removal from office or death.
Mr. Norstrud, who is the Chief Financial Officer of the Company, has been appointed to the Board of Directors until his respective successor is elected and qualified or until his earlier resignation, removal from office or death.
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|STEM CELL THERAPY INTERNATIONAL, INC.|
|Name:||Andrew J. Norstrud|
|Title:||Chief Financial Officer|
Date: August 1, 2008